Kathleen Frenette, Leslie Anne Montgomery, and Suzanne Zuckerman v. Alexion Pharmaceuticals Inc.

CourtDistrict Court, D. Massachusetts
DecidedMarch 20, 2026
Docket1:22-cv-11042
StatusUnknown

This text of Kathleen Frenette, Leslie Anne Montgomery, and Suzanne Zuckerman v. Alexion Pharmaceuticals Inc. (Kathleen Frenette, Leslie Anne Montgomery, and Suzanne Zuckerman v. Alexion Pharmaceuticals Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Massachusetts primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Kathleen Frenette, Leslie Anne Montgomery, and Suzanne Zuckerman v. Alexion Pharmaceuticals Inc., (D. Mass. 2026).

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS

Kathleen Frenette, et al., * * Plaintiffs, * * v. * Civil Action No. 1:22-cv-11042-IT * Alexion Pharmaceuticals Inc., * * Defendant. * *

MEMORANDUM & ORDER

March 20, 2026 TALWANI, D.J. In this employment dispute, Plaintiffs Kathleen Frenette, Leslie Anne Montgomery, and Suzanne Zuckerman assert claims against Defendants Alexion Pharmaceuticals, Inc. (“Alexion”) for age discrimination and retaliation. Plaintiffs assert that, in a 2020 restructuring resulting in additional jobs, Alexion used a “ruse” of terminating case managers and requiring them to re- apply through a process based solely on subjective interviews, resulting in disparate treatment of Plaintiffs based on their age. Compl. 1 [Doc. No. 1-1]. Now pending before the court is Alexion’s Motion for Summary Judgment [Doc. 90].1 For the reasons set forth herein, the Motion is GRANTED as to Plaintiffs’ retaliation claim and DENIED as to their discrimination claim. I. Background A. The Parties Alexion is a biopharmaceutical company based in Boston, Massachusetts. See Notice of Removal ¶ 12 [Doc. No. 1]. Alexion develops drug therapies for patients with “rare diseases[.]”

1 The court previously granted the motion as unopposed as to Defendant Mary-Sheila Leese. See Elec. Order [Doc. No. 116] (dismissing Count 2); Pls.’ Opp’n 18 [Doc. No. 97]. See Defs.’ Statement of Facts ¶ 1 (“Defs.’ SOF”) [Doc. No. 92]. Alexion’s Patient Services Organization (formerly called “OneSource”) provided patient support in connection with these therapies. Id. At the time of the actions challenged here, Frenette, Montgomery, and Zuckerman all

worked in the OneSource Neurology Group as Field Focused Case Managers. Frenette was 56 years old, Montgomery was 55 years old, and Zuckerman was 52 years old. Id. ¶¶ 62, 83, 98. Frenette had worked at OneSource since February 2013 (except for a few months in 2015 when she worked for a company that was then acquired by Alexion), Zuckerman since May 2014, and Montgomery since June 2015. Id. ¶¶ 54–57, 72, 91–92. Alexion categorized positions by numerical level, corresponding to duties and salary, and categorized Case Managers, including Field Focused Case Managers, as Level 8 positions. See Defs.’ SOF Ex. 1, ¶ 18 (“Leese Decl.”) [Doc. No. 92-1]. B. Alexion’s Restructuring of OneSource On September 24, 2020, Alexion announced a “restructuring” of OneSource to

accommodate anticipated growth. Id. ¶¶ 10–12. As part of the restructuring, the company renamed “OneSource” as “Patient Services” and designed a new organizational configuration for the department. Id. The restructuring announcement informed employees that 86 positions, including all Case Managers in Neurology, would be eliminated as of March 1, 2021. Def.’s SOF Ex. 5, at ECF 7–8 (“Reorg. PowerPoint”) [Doc. 92-5]; Leese Decl. ¶ 12 [Doc. No. 92-1]. The company also announced 101 new positions and encouraged the affected employees to apply for the new positions. See Leese Decl. ¶ 17 [Doc. No. 92]; Pls.’ Opp’n Ex. 15, at ECF 7 (“Reorg. FAQ”) [Doc. No. 96-15]; Reorg. PowerPoint at ECF 7–8 [Doc. 92-5]. Alexion stated it would inform affected employees whether they would be hired in a new role in Patient Services by the end of October 2020. See Reorg. PowerPoint at ECF 8 [Doc. No. 92-5]. On September 30, 2020, the new Patient Services job postings went live on Alexion’s website and employees were told to apply “to any role” in which they were interested by October

2, 2020. Reorg. FAQ at ECF 7 [Doc. No. 96-15]; see Reorg. PowerPoint at ECF 9 [Doc. 92-5]; Def.’s SOF Ex. 19 (“Ferguson and Montgomery Emails”) [Doc. No. 92-19]. After the positions were posted, managers reached out to affected employees to meet and discuss the new roles and application process. See Reorg. FAQ at ECF 7 [Doc. No. 96-15]. During the initial hiring process in October 2020, Alexion only reviewed internal candidates. See Leese Decl. ¶ 27 [Doc. No. 92- 1]. Among the new roles in Patient Services were two Level 7 positions: Patient Navigator and Patient Liaison. Id. ¶¶ 19–20 [Doc. No. 92-1]. Employees selected for these lower level positions would have a “grandfathered” base salary that matched their Level 8 positions, but with bonus and equity targets lowered, and only a one-time bonus in March 2022 in lieu of the lost

bonus and equity potential. See Reorg. FAQ at ECF 8 [Doc. No. 96-15]. Further, unlike Plaintiffs’ roles, the new lower level positions did not require significant travel and Alexion would not provide a car allowance after June 2021. Id. Additional new positions included: Patient Education Manager (“PEM”), categorized as Level 9, see Leese Decl. ¶ 21 [Doc. No. 92-1]; Senior Manager for Patient Engagement, also categorized as Level 9, see Defs.’ SOF Ex. 10, at ECF 2 [Doc. No. 92-10]2; and PEM Lead, categorized as Level 11, see Defs.’ SOF Ex. 9, at ECF 2 [Doc. No. 92-9].

2 Defendants assert both that this position was a level 10, see Leese Decl. ¶ 21 [Doc. No. 92-1], and that it was a level 9 position, see Defs.’ SOF ¶ 34 [Doc. No. 92]. Following the restructuring from OneSource to Patient Services, no Level 8 positions remained within the department. See Leese Decl. ¶ 18 [Doc. No. 92-1]. On October 6, 2020, Alexion hosted a “culture call” meeting, see Defs.’ Reply Ex. A [Doc. No. 100-1], during which it explained the interview process and referenced the “Interview Guide,”

a resource “designed to help [the hiring panel] conduct behavior-based interviews to gain insight into the candidate’s past behavior and performance[.]” Pls.’ Opp’n Ex. 43, at ECF 5 [Doc. No. 96- 43]. The company appointed four different panels, each “comprised of a mix of . . . management . . . and human resources personnel” to conduct a single interview of each employee. Leese Decl. ¶¶ 29–32 [Doc. No. 92-1]. The single-interview process was designed with the panels “pos[ing] four core questions to each applicant followed by a single, role-specific question for each position that the applicant sought.” Id. ¶ 29 “The four core questions . . . were designed to evaluate the applicant across the following areas: (1) Strategic Thinking; (2) Culture; (3) Matrix Leadership; and (4) External Orientation. . . . The role-specific questions were designed

to allow candidates to showcase their applicable skills and experiences for the particular roles at issue.” Id. ¶¶ 33–34. The different panels did not pose the same questions to each applicant for a specific role. Instead, Alexion’s People & Culture Partner Emily Ferguson reminded each of the panelists that “the questions [were] different for each panel[.]” Pls.’ Opp’n Ex. 20, at ECF 2 [Doc. No. 96-20]. Starting on October 8, 2020, the panels interviewed the employees who applied to new roles. Leese Decl. ¶ 29 [Doc. No. 92-1].3 Each panelist scored the interviewee on a scale from 1–5

3 Only three of the four panels (designated Panels B, C, and D) conducted interviews of the candidates who applied for the positions at issue here. See Defs.’ SOF Ex. 16 (“Interview for each question; the scores were then averaged. See id. Accordingly, for each role an employee interviewed for, the panel could assign a maximum of 25 points. See id. ¶ 30. Put another way, the panel assigned each interviewee a baseline score of 4–20, based on the core questions, and assigned an additional 1–5 points based on the question regarding the specific role. See id.4

C. Frenette’s Application Process Frenette applied to four positions, detailed further below. Frenette met with Liam Moy, the Senior Director of Neurology for Patient Services and the head of Plaintiffs’ department, prior to Frenette’s interview. Pls.’ Opp’n Ex. 1, ¶ 11 [Doc. No. 96-1] (Frenette Aff.). Frenette was interviewed for all four positions by a single panel on October 8, 2020. See Defs.’ SOF ¶¶ 59–61 [Doc. No. 92].

Free access — add to your briefcase to read the full text and ask questions with AI

Related

McDonnell Douglas Corp. v. Green
411 U.S. 792 (Supreme Court, 1973)
Furnco Construction Corp. v. Waters
438 U.S. 567 (Supreme Court, 1978)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Hodgens v. General Dynamics Corp.
144 F.3d 151 (First Circuit, 1998)
Che v. Massachusetts Bay Transportation Authority
342 F.3d 31 (First Circuit, 2003)
Samuel Mesnick v. General Electric Company
950 F.2d 816 (First Circuit, 1991)
Baker v. St. Paul Travelers Insurance
670 F.3d 119 (First Circuit, 2012)
Kelley v. Correctional Medical Services, Inc.
707 F.3d 108 (First Circuit, 2013)
Woodward v. Emulex Corporation
714 F.3d 632 (First Circuit, 2013)
Wheelock College v. Massachusetts Commission Against Discrimination
355 N.E.2d 309 (Massachusetts Supreme Judicial Court, 1976)
Psy-Ed Corporation v. KLEIN HIRSCH
947 N.E.2d 520 (Massachusetts Supreme Judicial Court, 2011)
Bulwer v. Mount Auburn Hospital
46 N.E.3d 24 (Massachusetts Supreme Judicial Court, 2016)
Verdrager v. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
50 N.E.3d 778 (Massachusetts Supreme Judicial Court, 2016)
Scarlett v. City of Boston
107 N.E.3d 1179 (Massachusetts Appeals Court, 2018)
Yee v. Massachusetts State Police
121 N.E.3d 155 (Massachusetts Supreme Judicial Court, 2019)
Blare v. Husky Injection Molding Systems Boston, Inc.
646 N.E.2d 111 (Massachusetts Supreme Judicial Court, 1995)

Cite This Page — Counsel Stack

Bluebook (online)
Kathleen Frenette, Leslie Anne Montgomery, and Suzanne Zuckerman v. Alexion Pharmaceuticals Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/kathleen-frenette-leslie-anne-montgomery-and-suzanne-zuckerman-v-alexion-mad-2026.